The Federal Circuit reversed summary judgment of noninfringement of a multi-core processor patent, holding that a pretrial stipulation establishing a 70% U.S. nexus applied to infringement — not just damages — and that prosecution history did not clearly disclaim the broader scope of apparatus claim
The Federal Circuit affirmed that U.S. Patent No. 8,458,689 — covering methods and apparatus for reprogramming automotive engine controllers — was invalid under the pre-AIA on-sale bar, holding that source code commands are not hearsay and that selling a device embodying a patented method triggers t
The Federal Circuit affirmed the PTAB’s finding that Universal Electronics’ voice-input remote control patent claims were unpatentable as obvious, in the latest chapter of the long-running patent battle between the two consumer electronics companies.
The Federal Circuit dismissed ironSource’s appeal of a PTAB post-grant review decision, holding that ironSource failed to demonstrate Article III standing because its evidence did not address the substitute claims actually at issue.
The Federal Circuit affirmed the ITC’s finding that imported marine air conditioning systems did not violate Section 337, holding that the asserted patent claims were anticipated by prior art and the accused products did not infringe remaining claims.
In a case of first impression, the Federal Circuit held that patents listing incorrect inventors are invalid when the omitted coinventor cannot be found to receive the notice and hearing required by 35 U.S.C. Section 256(b).
The Federal Circuit reversed the PTAB’s obviousness finding against Virtek’s laser-alignment patent, holding that showing a skilled artisan had the knowledge to make a combination is insufficient for motivation to combine — there must also be a reason why they would have done so.
The Federal Circuit affirmed that importing patented medical devices for a U.S. conference fell within the 35 U.S.C. § 271(e)(1) safe harbor because the importation bore a reasonable relationship to obtaining FDA approval, even if the conference also served commercial purposes.
The Federal Circuit reversed a district court’s indefiniteness ruling on a lithium-ion battery patent, holding that two claim limitations are not contradictory—and therefore not indefinite—if they can both be satisfied simultaneously, even if one limitation makes an element optional while a na
The Federal Circuit affirmed obviousness of Pfizer’s pneumococcal vaccine patent, clarifying that the result-effective variable doctrine applies to optimize claim ranges even when the prior art does not disclose an overlapping range — expanding the scope of when routine optimization can render